Johnson & Johnson (NYSE:JNJ) Trading Up 2.6% – Here’s Why

Shares of Johnson & Johnson (NYSE:JNJ) traded up 2.6% during mid-day trading on Monday . The company traded as high as $209.90 and last traded at $209.7910. 11,726,784 shares changed hands during mid-day trading, an increase of 47% from the average session volume of 7,983,578 shares. The stock had previously closed at $204.39.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JNJ. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a research note on Friday. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $240.00 target price on Johnson & Johnson in a research report on Wednesday, December 17th. Finally, Scotiabank started coverage on Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target for the company. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Trading Up 2.6%

The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $203.34 and a 200-day moving average price of $185.38. The company has a market capitalization of $505.45 billion, a price-to-earnings ratio of 20.25, a PEG ratio of 2.10 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently modified their holdings of JNJ. Abich Financial Wealth Management LLC purchased a new position in Johnson & Johnson in the 3rd quarter worth about $26,000. Clayton Financial Group LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $28,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. acquired a new position in Johnson & Johnson in the 3rd quarter worth approximately $41,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.